A Phase 2/3 interventional study of IBI311 and placebo in Thyroid Eye Disease, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-08.
Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.
Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 10th largest by enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2023, is one of 3 in phase 2/3, and was the 19th registered.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
Browse Graves Ophthalmopathy studies →25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–80
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–75
Candid Therapeutics · Sites in China
Ages 18–75
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18–75
Shanghai Changzheng Hospital · Sites in China
Ages 18–70 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 16 · Phase 4 8
First in 2010; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 115 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 64 across the 45 interventional studies, 125 across the 10 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Innovent Biologics (Suzhou) Co. Ltd., one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Innovent Biologics, Inc. has 6 studies filed under Graves Ophthalmopathy — fewer than ten, so there is no comparison to draw.
12 of the studies in Graves Ophthalmopathy with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06989918Phase 3Minghui Pharmaceutical (Hangzhou) LtdMHB018A Treatment in Patients With Active Thyroid Eye Disease | 2026-12 |
| NCT07113262Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease | 2026-12-31 |
| NCT07211776Phase 3Zai Lab (Shanghai) Co., Ltd.A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease | 2027-03-14 |
| NCT07720635Phase 3Beijing Kanghong Biological Medicine Co., Ltd.A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease | 2027-04 |
| NCT07720648Phase 3Beijing Kanghong Biological Medicine Co., Ltd.A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease | 2027-05 |
Add all 12 to your calendar (.ics) → With an account.
Among the 55 studies in Graves Ophthalmopathy with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-masked, placebo-controlled Phase II/III study in subjects with active thyroid eye disease. Approximately 114 subjects meeting study eligibility criteria will be randomly assigned to IBI311 or placebo on day 1 (D1) in a 2:1 ratio stratified by smoking status
Key Inclusion Criteria:
Key Exclusion Criteria:
Subjects will be ineligible for study participation if they meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with TED will be randomized to receive 4 intravenous infusions of Placebo with an interval of 3 weeks for phase II and 8 intravenous infusions of Placebo with an interval of 3 weeks for phase III.
Biological: IBI311 · Biological: placebo
Participants with TED will be randomized to receive 4/8 intravenous infusions of IBI311 with an interval of 3 weeks for phase II/III.
Biological: IBI311
10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions for phase II/III.
4 does of placebo for phase II; 8 does of placebo for phase III.
The proptosis responder rate of the study eye (defined as percentage of subjects with a ≥ 2mm reduction from Baseline in proptosis in the study eye, without deterioration [≥ 2 mm increase] of proptosis in the non-study eye).
proptosis assessment: amount of protrusion of the eye from the orbital rim measured by Hertel exophthalmometer
Time frame: Week 12 for phase II, Week 24 for phase III
The overall responder rate in the study eye.
Responder rate were defined as participants with a reduction in clinical activity score (CAS, see Secondary Outcome Measure 2 description for details) of ≥ 2 points, and a reduction in proptosis of ≥ 2 mm in the study eye, and no deterioration (increase in CAS of ≥ 2 points or increase in proptosis of ≥ 2 mm) in the non-study eye.)
Time frame: Week12 and Week24 for phase II, Week 24 for phase III
Percentage of subjects with a CAS value of 0 or 1 in the study eye.
According to the 7-item European Group on Graves' Ophthalmopathy (EUGOGO) amendment, CAS was used to evaluate clinical activity. For each of the following items, one point is given: spontaneous orbital pain, gaze evoked orbital pain, eyelid swelling that is considered to be due to active (inflammatory phase) Graves' ophthalmopathy (GO), eyelid erythema, conjunctival redness that is considered to be due to active (inflammatory phase) GO, chemosis, and inflammation of caruncle or plica. The sum of these points is the total score, with 0 indicating no clinical activity and 7 indicating the most severe clinical activity.
Time frame: Week12 and Week24 for phase II, Week 24 for phase III
Mean Change of the CAS value in the study eye.
Time frame: Baseline to Week 12 and Week 24 for phase II
Mean change from Baseline in proptosis measurement in the study eye.
proptosis measurement: see Primary Outcome Measure 1 description for details
Time frame: Baseline to Week 12 and Week 24 for phase II, Baseline to Week 24 for phase III
The proptosis responder rate of the study eye.
proptosis responder rate: see Primary Outcome Measure 1 description for details
Time frame: Week 24 for phase II
The diplopia responder rate of the study eye.
Time frame: Week12 and Week24 for phase II, Week 24 for phase III
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Dec 2023, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IBI311
Innovent Biologics (Suzhou) Co. Ltd. →